ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc (RXRX)

7.24
-0.45
(-5.85%)
Closed February 01 3:00PM
7.2499
0.0099
(0.14%)
After Hours: 6:59PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
7.2499
Bid
7.22
Ask
7.27
Volume
21,198,319
7.15 Day's Range 7.96
5.60 52 Week Range 15.74
Market Cap
Previous Close
7.69
Open
7.91
Last Trade
5
@
7.27
Last Trade Time
Financial Volume
US$ 158,666,450
VWAP
7.4849
Average Volume (3m)
15,168,307
Shares Outstanding
286,640,833
Dividend Yield
-
PE Ratio
-6.31
Earnings Per Share (EPS)
-1.14
Revenue
44.58M
Net Profit
-328.07M

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery... Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
Recursion Pharmaceuticals Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RXRX. The last closing price for Recursion Pharmaceuticals was US$7.69. Over the last year, Recursion Pharmaceuticals shares have traded in a share price range of US$ 5.60 to US$ 15.74.

Recursion Pharmaceuticals currently has 286,640,833 shares outstanding. The market capitalization of Recursion Pharmaceuticals is US$2.20 billion. Recursion Pharmaceuticals has a price to earnings ratio (PE ratio) of -6.31.

Recursion Pharmaceuticals (RXRX) Options Flow Summary

Overall Flow

Bullish

Net Premium

976k

Calls / Puts

100.00%

Buys / Sells

60.00%

OTM / ITM

14.29%

Sweeps Ratio

0.00%

RXRX Latest News

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 PR Newswire VANCOUVER, BC, Jan. 17, 2025 USA News GroupΒ News CommentaryΒ  Issued on behalf of Avant Technologies...

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 Canada NewsWire VANCOUVER, BC, Jan. 17, 2025 USA News GroupΒ News CommentaryΒ  Issued on behalf of Avant Technologies...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.3901-5.106020942417.648.2456.72178056467.31838837CS
4-0.0601-0.8221614227097.318.666.2166292227.18937925CS
120.38995.683673469396.869.555.6151683077.02397101CS
26-0.7501-9.3762589.555.693763266.92835522CS
52-2.5001-25.64205128219.7515.745.675942388.07773669CS
156-3.5301-32.746753246810.7816.7454.5442095248.6473559CS
260-22.7501-75.83366666673042.814.5435168959.3402627CS

RXRX - Frequently Asked Questions (FAQ)

What is the current Recursion Pharmaceuticals share price?
The current share price of Recursion Pharmaceuticals is US$ 7.2499
How many Recursion Pharmaceuticals shares are in issue?
Recursion Pharmaceuticals has 286,640,833 shares in issue
What is the market cap of Recursion Pharmaceuticals?
The market capitalisation of Recursion Pharmaceuticals is USD 2.2B
What is the 1 year trading range for Recursion Pharmaceuticals share price?
Recursion Pharmaceuticals has traded in the range of US$ 5.60 to US$ 15.74 during the past year
What is the PE ratio of Recursion Pharmaceuticals?
The price to earnings ratio of Recursion Pharmaceuticals is -6.31
What is the cash to sales ratio of Recursion Pharmaceuticals?
The cash to sales ratio of Recursion Pharmaceuticals is 46.43
What is the reporting currency for Recursion Pharmaceuticals?
Recursion Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Recursion Pharmaceuticals?
The latest annual turnover of Recursion Pharmaceuticals is USD 44.58M
What is the latest annual profit for Recursion Pharmaceuticals?
The latest annual profit of Recursion Pharmaceuticals is USD -328.07M
What is the registered address of Recursion Pharmaceuticals?
The registered address for Recursion Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Recursion Pharmaceuticals website address?
The website address for Recursion Pharmaceuticals is www.recursion.com
Which industry sector does Recursion Pharmaceuticals operate in?
Recursion Pharmaceuticals operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TCTMTCTM Kids IT Education Inc
US$ 0.764
(321.87%)
731.1M
REBNReborn Coffee Inc
US$ 3.31
(63.05%)
55.54M
FCUVFocus Universal Inc
US$ 5.87
(56.62%)
1.73M
SOPASociety Pass Inc
US$ 1.54
(56.50%)
13.87M
CYCNCyclerion Therapeutics Inc
US$ 3.92
(54.33%)
82.57M
ENVBEnveric Biosciences Inc
US$ 2.0899
(-46.41%)
1.57M
NIVFNewGenIvf Group Ltd
US$ 0.1489
(-42.51%)
14.8M
GLSTGlobal Star Acquisition Inc
US$ 8.83
(-39.10%)
23.89k
PRPHProPhase Labs Inc
US$ 0.2633
(-38.02%)
872.46k
SPGCSacks Parente Golf Inc
US$ 0.5601
(-37.86%)
7.27M
TCTMTCTM Kids IT Education Inc
US$ 0.764
(321.87%)
731.1M
NVDANVIDIA Corporation
US$ 120.07
(-3.67%)
388.5M
RIMEAlgorhythm Holdings Inc
US$ 0.02565
(5.12%)
341.8M
CLEUChina Liberal Education Holdings Ltd
US$ 0.1938
(30.77%)
237.15M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0355
(-11.25%)
236.44M

RXRX Discussion

View Posts
bwrbad bwrbad 1 day ago
YouTube influencer position - write or call cGibson@recursion.com
πŸ‘οΈ0
TucsonPhil TucsonPhil 3 days ago
Exactly, when we see the lending fees start to rise, then I will buy more. Brokers always make money, even when investors lose.
πŸ‘οΈ0
bwrbad bwrbad 4 days ago
they all do etard fidal TDA, but that gives the opportunity to buy low. This RxRx defines the future of MED world in AI stage- just buying little little within affordability. definitively it will grow like MSTF GOOG AAPL NVDA AMZN.., All drug lords pfizer, j&j eli, merck roche AZ BMS are lining up behind, just give few months to a year for first $100
πŸ‘οΈ0
TucsonPhil TucsonPhil 4 days ago
Fidelity is loaning shares to shorts.
πŸ‘οΈ0
bwrbad bwrbad 4 days ago
next piece of clinical update will take it above 20 and after that it is in different league.
πŸ‘οΈ0
bwrbad bwrbad 1 week ago
Sure looks like early days of ISRG ILMN,
πŸ‘οΈ0
TucsonPhil TucsonPhil 1 week ago
Nvidia invested $50M in this company. ARK is a holder. This will be huge, once their first find gets FDA approval, and proof of concept is secured.
👍️ 1
bwrbad bwrbad 1 week ago
interesting no posters in this
future $200 - $300 stock, and that future not far - see the quality of clinical data, target diseases, and the time it took to reach there - not standard 20 ys but 3y to ph3 and a large advancing failure resistant AI powered pipeline
πŸ‘οΈ0
bwrbad bwrbad 1 week ago
change of heart -going up.
πŸ‘οΈ0
bwrbad bwrbad 1 week ago
rxrx WORLD
πŸ‘οΈ0
bwrbad bwrbad 2 weeks ago
promised to accumulate 10k shares before Q end and hold for years. predict this issue never go BK, do RS, and one day go beyond 200+ like established big cap security issues.
πŸ‘οΈ0
bwrbad bwrbad 2 weeks ago
bandwagon
πŸ‘οΈ0
bwrbad bwrbad 3 weeks ago
believe in miracle ----- come to RXRX------
πŸ‘οΈ0
TucsonPhil TucsonPhil 3 weeks ago
Looks like Lilly is late to the party.

https://www.statnews.com/2025/01/10/eli-lilly-andreessen-horowitz-500-million-venture-fund-ai-focus/
πŸ‘οΈ0
bwrbad bwrbad 4 weeks ago
cursion-re-cursion in flame after FDA REC 3565 blessings
πŸ‘οΈ0
bwrbad bwrbad 4 weeks ago
Gibson🤢🥵🥶😷Gibson
πŸ‘οΈ0
bwrbad bwrbad 4 weeks ago
baby nvda
👍 1
bwrbad bwrbad 1 month ago
balding haircut at RXRX
πŸ‘οΈ0
Monksdream Monksdream 1 month ago
RXRX, under $7
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
out for now, let CEO work his magic if he has one under his sleeve
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
is something wrong with RxRx, it looked promising based on what said to public. but something not right. ground shaken up. - like trouble.
what wrong with the CEO. if this continues that is bad sign for future of the company and the CEO.
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
RXRX
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
RxRx partnership: GOOG NVDA MSFT Roche/Genentech Bayer Bristol Myers Squibb Sanofi Merck ......
👍 1
bwrbad bwrbad 2 months ago
RxRx M&A: Valence –Cyclica - Exscientia
Valence – a leader in generative AI and deep learning models
Cyclica - a deep learning engine that predicts the polypharmacology of small molecules in drug discovery.
Exscientia - AI-driven precision medicine
RXRX - Regenerative AI - TechBio powerhouse
undergoing post merger reorganization, some job cuts
enough cash to fund through 2027
Ark Q3 2024 Stake: $215.9 million
Hedge Fund Investors Q3 2024:: 16
more than ten drugs in trials.
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
market up big and RxRx ignored,
if quantum computing which is 7-10 years away getting attention now, then this should be in the rocket heading for stratosphere.
πŸ‘οΈ0
TucsonPhil TucsonPhil 2 months ago
RXRX seeing some promising results in early trials. Proof of concept will solidify belief in the platform.

If cost of trials can be reduced, by less attrition of candidates, then they should see more licensing agreements, and funding, from pharma companies IMO.
👍️ 1
bwrbad bwrbad 2 months ago
Revenue (ttm) 65.18M; Quarterly Revenue Growth (yoy) 147.60%
Total Cash (mrq) 427.65M; Total Debt (mrq) 90.62M
Shares Outstanding 6 388.94M; Float 8 252.42M
clinical trial : REC-994 in Phase 2, REC-2282 in Phase 2/3; few other in phase 1 and 2, all in less than 2 year not 15-18 years (conventional).

% Held by Institutions 1 69.40% Shares Short (Nov 15, 2024) 4 64.57M 25%
👍️ 1
JJ8 JJ8 2 months ago
Rxrx share price Long Tail Up since 06 Dec 2024.
πŸ‘οΈ0
paperman paperman 2 months ago
Phase 1 news expected tonight at conference.
πŸ‘οΈ0
paperman paperman 2 months ago
Phase 1 news expected tonight at conference.
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
this is one magnificent AI drug discovery platform - be household name like google tesla Microsoft ...
πŸ‘οΈ0
JJ8 JJ8 2 months ago
Bought it yesterday at $6.60

Today it's up about 22%.

Same story with 2 other stocks and they all go up today more than 20%!

Whoa! IN CREDIBLE!
πŸ‘οΈ0
TucsonPhil TucsonPhil 2 months ago
Agreed, but there will be wild swings, until they get their footing with clinical trials proving the concept works. Trade it until then, and keep one foot in the door for surprise announcements.
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
RxRx going to be top player in future pharma drug discovery
πŸ‘οΈ0
TucsonPhil TucsonPhil 2 months ago
Good company, but MMs playing games this morning. Insider buying? News? Who knows? Missed this runup, but will wait for the dip again.
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
GOOG -- RxRx -- NVDA -- RxRx -- MSFT
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
agree but better, much bigger scope, on way to become a high flying company of the future
price target 150 in two year
πŸ‘οΈ0
uksausage uksausage 2 months ago
no it is the PLTR of Drug discovery
both rely on NVDA to run fast
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
started buying little little- this is NVDA of DRUG DISCOVERY
πŸ‘οΈ0
ToucanYoucan ToucanYoucan 2 months ago
$RXRX - That's why I'm planning to steadily accumulate shares - with the hope that one or more of these new treatments materializes.
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
high potential if delivers,
πŸ‘οΈ0
TucsonPhil TucsonPhil 2 months ago
Good gains in past week, but looks like it is getting ready to drift lower again.
πŸ‘οΈ0
TucsonPhil TucsonPhil 2 months ago
First patient dosed.

https://ir.recursion.com/news-releases/news-release-details/recursion-announces-first-patient-dosed-phase-12-clinical-study
πŸ‘οΈ0
lambchops lambchops 2 months ago
Glad to see the uptick! Was beaten down for a while. Too good of stock to be down for long.

LC

RXRX
👍️ 1
ToucanYoucan ToucanYoucan 2 months ago
$RXRX - Having a huge day here!!
πŸ‘οΈ0
ToucanYoucan ToucanYoucan 2 months ago
$RXRX - Nice move up today! This will take a little time to find its footing pps-wise after the merger...imo
πŸ‘οΈ0
TucsonPhil TucsonPhil 3 months ago
Many foreign countries supplying pharmaceuticals to U.S. at exorbitant markups.

Will anything be done about that? I do not believe tariffs will help with that problem, since people either pay, whatever the cost, or suffer and die.
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
RXRX 10Q 11/6
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
RXRX under $10
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
RXRX under $10
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock